CD28 and cancer: As such, first-generation CARs lacking costimulation showed low persistence and modest clinical outcomes in a cancer setting (68–70), and the provision of costimulation, mainly CD28 (71) or 4-1BB (50), in a second-generation CAR format greatly increased their persistence and clinical success (72).